Tag: 100-200

On April 2, 2021, Zhang, Zhihu; Tang, Zheng; Wang, Hao; Gao, Sen; Cui, Chaohui published a patent.HPLC of Formula: 121129-31-5 The title of the patent was Preparation of 3,3-dimethyl-2-oxobutanoic acid and its sodium salt. And the patent contained the following:

The invention relates to preparation of sodium 3,3-dimethyl-2-oxobutanoate and its sodium salt, which has the advantages of environmental friendliness and stability. The 3,3-dimethyl-2-oxobutyric acid and sodium salt thereof were prepared by the following steps: oxidation of sodium 2-hydroxy-3,3-dimethylbutanoate and sodium chlorite to obtain sodium 3,3-dimethyl-2-oxobutanoate; (2) acidification sodium 3,3-dimethyl-2-oxobutanoate to obtain free acid. The experimental process involved the reaction of Methyl 2-hydroxy-3,3-dimethylbutanoate(cas: 121129-31-5).HPLC of Formula: 121129-31-5

The Article related to preparation dimethyloxobutanoic acid sodium oxidation acidification, Aliphatic Compounds: Carboxylic Acids and Peroxycarboxylic Acids and Their Sulfur-Containing Analogs and Salts and other aspects.HPLC of Formula: 121129-31-5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 21, 2022, Zhang, Wen-Wen; Liu, Chen-Xu; Yang, Pusu; Zhang, Su-Zhen; Gu, Qing; You, Shu-Li published an article.Safety of Ethyl indolizine-1-carboxylate The title of the article was Rhodium-Catalyzed Atroposelective C-H/C-H Cross-Coupling Reaction between 1-Aryl Isoquinoline Derivatives and Indolizines. And the article contained the following:

Rhodium-catalyzed asym. oxidative C-H/C-H cross-coupling reaction between 1-aryl isoquinolines and indolizines was disclosed. With a matched pair of SCpRh complex and chiral carboxylic acid, enantioselective 2-fold C-H/C-H cross-coupling reactions between 1-aryl isoquinolines and indolizines provide a variety of axially chiral bi(hetero)aryls in excellent yields and enantioselectivity (up to 96% yield and 98% ee). Mechanistic studies suggest that both C-H cleavages are likely reversible. The experimental process involved the reaction of Ethyl indolizine-1-carboxylate(cas: 93476-46-1).Safety of Ethyl indolizine-1-carboxylate

The Article related to indolizine heterobiarene rhodium catalyst enantioselective cross coupling reaction, heterobiaryl indolizine preparation, Heterocyclic Compounds (One Hetero Atom): Other Areno- and Diarenopyridines (Acridines, Quinolizines, etc.) and other aspects.Safety of Ethyl indolizine-1-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Dawson, Marcia I.; Chan, Rebecca; Hobbs, Peter D.; Chao, Wanru; Schiff, Leonard J. published an article in 1983, the title of the article was Aromatic retinoic acid analogs. 2. Synthesis and pharmacological activity.Computed Properties of 86239-00-1 And the article contains the following content:

I (R1 = R3 = H; R2 = H, Et) were prepared as potential agents for the treatment of epithelial cancer, psoriasis, and cystic acne. I (R1 = F; R2 = H, Et; R3 = H), I (R1 = H; R2 = H, Et; R3 = F), II (X = O, S), and III were also prepared except for II (X = O), this compounds with reversed keratinization in hamster tracheal organ culture and inhibited the induction of ornithine decarboxylase in mouse epidermis by a tumor promoter. The experimental process involved the reaction of Ethyl 3-fluoro-4-methylbenzoate(cas: 86239-00-1).Computed Properties of 86239-00-1

The Article related to anticancer retinoic acid analog, psoriasis treatment retinoic acid analog, acne treatment retinoic acid analog, Terpenes and Terpenoids: Higher Terpenes and Miscellaneous Terpenoids, Including Carotenoids and Vitamins K and other aspects.Computed Properties of 86239-00-1

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 3, 2014, Zeng, Qingping; Faris, Mary; Mollard, Alexis; Warner, Steven L.; Flynn, Gary A. published a patent.SDS of cas: 872046-08-7 The title of the patent was Preparation of heteroarylaminonaphthyridinone derivatives for use as multiple kinase pathway inhibitors. And the patent contained the following:

Title compounds I [R1 = (un)substituted azaheteroaryl; R2 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R3 = H, alkyl, cycloalkyl, (un)substituted alkenyl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as multiple kinase pathway inhibitors. Thus, e.g., II was prepared by a multistep procedure (preparation given). Select I were evaluated in DoHH2 cell cycle proliferation assays, e.g., II demonstrated an EC50 value of <1 μM. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).SDS of cas: 872046-08-7

The Article related to naphthyridinone heteroarylamino preparation multiple kinase pathway inhibitor, Heterocyclic Compounds (One Hetero Atom): Other Areno- and Diarenopyridines (Acridines, Quinolizines, etc.) and other aspects.SDS of cas: 872046-08-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 1, 1984, there was a patent about antitumor agents.COA of Formula: C10H11FO2 The title of the patent was Aromatic retinoids. And the patent contained the following:

Antineoplastic title compds I (R = alkoxy, OH; R1 = H, F; R2 = H, halo, OH, alkyl, alkoxy) were prepared by condensation of phosphonates II with β-ionone in the presence of LiN(CHMe2)2. Thus, 5.1 g II (R = OEt, R1 = F, R2 = H) in THF was added to a mixture of HN(CHMe2)2, hexane, and BuLi at -78° over 5 min, the resulting mixture allowed to react for 15 min, 4.8 g β-ionone in THF added at -78°, and the resulting mixture allowed to react at -78° for 30 min and then at room temperature overnight to give 2.69 g I (R = OEt, R1 = F, R2 = H). I inhibited trachea keratinization in hamsters and ornithine decarboxylase release induced by 12-O-tetradecanoylphorbol 13-acetate. The experimental process involved the reaction of Ethyl 3-fluoro-4-methylbenzoate(cas: 86239-00-1).COA of Formula: C10H11FO2

The Article related to aromatic retinoid antitumor, Terpenes and Terpenoids: Higher Terpenes and Miscellaneous Terpenoids, Including Carotenoids and Vitamins K and other aspects.COA of Formula: C10H11FO2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Zhang, Yadong; Haske, Wojciech; Cai, Dengke; Barlow, Stephen; Kippelen, Bernard; Marder, Seth R. published an article in 2013, the title of the article was Efficient blue-emitting electrophosphorescent organic light-emitting diodes using 2-(3,5-di(carbazol-9-yl)phenyl)-5-phenyl-1,3,4-oxadiazole as an ambipolar host.COA of Formula: C10H14O3 And the article contains the following content:

2-(3,5-Di(carbazol-9-yl)phenyl)-5-phenyl-1,3,4-oxadiazole, 1, was synthesized from the reaction of 3,5-di(carbazol-9-yl)benzohydrazide and tri-Me orthobenzoate at 185 °C. Compound 1 exhibits a glass-transition temperature of 120 °C, a reversible reduction at a half-wave potential of -2.34 V vs. ferrocenium/ferrocene, and an adiabatic triplet energy of 2.73 eV. Organic light-emitting diodes were fabricated using: solution-processed poly[6-(9H-carbazol-9-yl)-9-(4-vinylbenzyl)-9H-3,9′-bicarbazole] as the hole-transport layer; a vacuum-deposited emissive layer composed of 1 as a host and bis[(4,6-di-fluorophenyl)pyridinato-N,C2′](picolinato-N,O)iridium or fac-tris(2-phenylpyridinato-N,C2′)iridium as blue- or green-emitting phosphorescent guest mols., resp.; and vacuum-deposited 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline or 3-([1,1′-biphenyl]-4-yl)-5-(4-(tert-butyl)phenyl)-4-phenyl-4H-1,2,4-triazole as the electron-transport layer. External quantum efficiencies of up to 21 and 25% were obtained for blue- and green-emitting devices, resp. The experimental process involved the reaction of (Trimethoxymethyl)benzene(cas: 707-07-3).COA of Formula: C10H14O3

The Article related to blue emitting pholed carbazolyl phenyl oxadiazole ambipolar host, Optical, Electron, and Mass Spectroscopy and Other Related Properties: Spectrometers and Optical Apparatus and other aspects.COA of Formula: C10H14O3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 15, 2021, Hou, Bao-Long; Li, Li-Xuan; Li, Chuang-Chuang published an article.Application In Synthesis of Methyl 2-cyclopentanonecarboxylate The title of the article was Synthesis of the Bridged [5-7-7] Tricyclic Core of Eurifoloid A. And the article contained the following:

We herein describe a new approach for the efficient and asym. construction of the tricyclic core (I) of eurifoloid A, which possesses a unique and highly strained bicyclo[4.4.1] ring system. A rhodium-catalyzed intramol. [3 + 2] dipolar cycloaddition was developed to install synthetically challenging bridged bicyclo[4.3.1] ring systems. The reported chem. shows the feasibility of constructing the eurifoloid A framework using a diastereoselective intramol. [3 + 2] cycloaddition and a ring enlargement. The experimental process involved the reaction of Methyl 2-cyclopentanonecarboxylate(cas: 10472-24-9).Application In Synthesis of Methyl 2-cyclopentanonecarboxylate

The Article related to eurifoloid a bridged tricyclic core preparation, Terpenes and Terpenoids: Diterpenes (C20), Including Gibberellins, Retinoids, Quassinoids, and Tocopherols and other aspects.Application In Synthesis of Methyl 2-cyclopentanonecarboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 8, 2021, Wu, Lingyun; Wang, Cailin; Xu, Xiongbin; Tong, Haijun; Chen, Shuhui published a patent.HPLC of Formula: 37480-41-4 The title of the patent was Preparation of heteroaryl compounds as PD-1/PD-L1 inhibitors for treatment of cancer. And the patent contained the following:

The title compounds represented by general formula I [wherein ring A is selected from Ph, 5-10 membered heteroaryl or 5-10 membered heterocycloalkenyl; L is selected from a single bond, -C(=O)NH-, -CH=CH-, -O-CH2- or -NH-; X is selected from -CH- or N; when Y is selected from a single bond, -CH2- or -CH(CH3)-, Z is selected from NR4, or when Y is selected from NR5, Z is selected from -CH2-, where R4 and R5 are each independently selected from H, C1-6 alkyl, C1-6 alkyl-NH-, C3-8 cycloalkyl, etc.; R1 is selected from H, C1-3 alkyl, C1-3 alkoxy, pyridyl-C1-3 alkane-O- or C1-3 alkyl-NH-; R2 and R3 are each independently selected from H, F, Cl, Br, I, CN, etc.; R6 is selected from H, C1-6 alkyl, C0-6 alkyl-C3-6 cycloalkyl, C0-6 alkyl-3-10 membered heterocycloalkyl, C0-6 alkyl-NH-C1-6 alkyl, etc.] or pharmaceutically acceptable salts or isomers thereof were prepared as PD-1/PD-L1 inhibitors. For example, compound II was prepared in a multi-step synthesis. The title compounds can be used for the treatment of cancers. The experimental process involved the reaction of Methyl 1-methyl-4-oxocyclohexanecarboxylate(cas: 37480-41-4).HPLC of Formula: 37480-41-4

The Article related to preparation heteroaryl compound pd1 pdl1 inhibitor treatment human cancer, benzoxazole pyridine naphthalene thiazole pyrazine pyrazole pyrimidine, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.HPLC of Formula: 37480-41-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 29, 2007, Abbott, Philip; Bonnert, Roger Victor; Brough, Stephen; Chohan, Kamaldeep; McInally, Thomas; Thom, Stephen; Isobe, Yoshiaki; Nakamura, Kei; Tojo, Shingo published a patent.Electric Literature of 142327-44-4 The title of the patent was Purine derivatives for the treatment of viral or allergic diseases and cancers. And the patent contained the following:

Purine derivatives, such as I [R = N-bound nitrogen containing heterocycle, such as 3-pyrrolidinyl, 3-azetidinyl or 1-methyl-4-piperidinyl; R3 = CH2CO2Me, R4 = H, or R3 = H, R4 = CH2CO2Me; X = alkylene linking group, such as (CH)n, n = 3, 4], were prepared for use in immunomodulating pharmaceutical compositions which are useful in the treatment of diseases or conditions in which modulation of TLR7 activity is beneficial. These diseases or conditions may include allergic or viral diseases, cancers, asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis. Thus, purine derivative I [R = 4-piperidinyl, R3 = CH2CO2Me, R4 = H; X = (CH2)3] was prepared in 8 steps starting from 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine, BuONa, Br(CH2)3NHCO2CMe3, 4-oxo-1-piperidinecarboxylic acid tert-Bu ester, and OHC-3-C6H4CH2CO2Me. The prepared purine derivatives were tested for interferon inducing activity in rat spleen cells and for activation of recombinant human TLR7. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Electric Literature of 142327-44-4

The Article related to purine derivative preparation immunomodulator toll like receptor activity, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Electric Literature of 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 22, 2007, McInally, Thomas; Thom, Stephen; Wada, Hiroki published a patent.Product Details of 142327-44-4 The title of the patent was Purine derivatives having immunomodulating properties. And the patent contained the following:

Purine derivatives, such as I [R = amino group, such as NMe2 or NHMe, or a N-bound nitrogen containing heterocycle, such as 1-pyrrolidinyl or 4-methyl-1-piperazinyl; X = alkylene linking group, such as (CH2)m, m = 3, 4; X1 = alkylene linking group, such as (CH2)n, n = 2, 3], were prepared for use in immunomodulating pharmaceutical compositions which are useful in the treatment of diseases or conditions in which modulation of TLR7 activity is beneficial. These diseases or conditions may include allergic or viral diseases, cancers, asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis. Thus, purine derivative I [R = NMe2, X = X1 = (CH2)3] was prepared in 10 steps starting from 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine, BuONa, Br(CH2)3Br, H2N(CH2)3OH, and BrCH2-3-C6H4CH2CO2Me. The prepared purine derivatives were tested for interferon inducing activity in rat spleen cells and for activation of recombinant human TLR7. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Product Details of 142327-44-4

The Article related to purine derivative preparation immunomodulator toll like receptor activity, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Product Details of 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics